Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-06-19

AUTHORS

J. P. Desilles, C. Gregoire, C. Le Cossec, J. Lambert, O. Mophawe, M. R. Losser, F. Lambiotte, S. Le Tacon, M. Cantier, N. Engrand, P. Trouiller, J. Pottecher

ABSTRACT

ObjectivesSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for the treatment of cystic fibrosis, which cleaves extracellular DNA and may break up cell-free DNA, loosening sticky mucus in the distal airways and reducing NETs-induced toxicity on alveolar pneumocytes. The COVIDornase trial intends to define the impact of aerosolized intra-tracheal dornase alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs.Trial designCOVIDornase is a prospective, randomized, controlled, 2-arm (1:1 ratio), multicentric, open-label clinical trial.ParticipantsThe study will recruit mechanically ventilated patients hospitalized in the intensive care unit (ICU) in the recruiting centres (at the time of writing: The Rothschild foundation hospital in Paris, the Strasbourg university hospitals, and Metz-Thionville hospital) who have been diagnosed with COVID-19 and meet ARDS criteria.Inclusion criteria- Adult patient (age ≥ 18 years old);- Hospitalized in ICU;- With severe COVID-19 pneumonia and ARDS according to Berlin criteria (PaO2/FiO2 < 300 and PEEP > 5 cmH2O);- Intubated for less than 8 days;- With an anticipated duration of mechanical ventilation > 48 hours;- Carrier of an arterial catheter;- For whom 4 PaO2/FiO2 values over the preceding 24 hours are available;Non-inclusion criteria- Known hypersensitivity to dornase alfa or any of its excipients;- Pregnant or breastfeeding status;- Patient under legal protection.Intervention and comparatorIntervention 1, Study groupDornase alfa (Pulmozyme®, Roche, Switzerland) will be administered by aerosol, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer (Aerogen Solo®, Aerogen, Ireland). The remainder of the management will be performed in accordance with good clinical practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH2O, tracheal balloon pressure check every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30 cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2 < 150, early enteral nutrition, glycemic control and a sedation protocol based on the RASS score.Intervention 2, ComparatorPatients will receive usual care in accordance with good practice (as detailed above), without aerosols.Main outcomesThe primary outcome is the occurrence of at least one grade improvement between D0 (inclusion) and D7 in the ARDS scale severity (Berlin criteria). For instance from “severe” to “moderate” or from “moderate” to “mild”.RandomisationAll consecutive patients meeting the inclusion criteria will be randomised 1:1 using an eCRF-based, computer-generated randomisation table, either to the dornase alfa arm or to the control arm. An interim analysis will be performed after inclusion of 20 patients. Inclusions may be stopped at the interim analysis per data safety and monitoring board (DSMB) advice, if statistical analyses conclude on the futility or efficacy of the intervention or by other DSMB decision.Blinding (masking)The participants and caregivers will not be blinded to study group assignment. Those assessing the outcomes will be blinded to study group assignment.Numbers to be randomised (sample size)Fifty patients will be randomized to each group, 100 patients in total.Trial StatusProtocol version number 2, April 29th, 2020. Recruitment is ongoing. The trial started recruitment on the 21st April 2020. We estimate recruitment will finish August 21st 2020.Trial registrationThe trial was registered in ClinicalTrials.gov on 21 April 2020, updated on 8 May 2020. Trial registration number is NCT04355364.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated. This Letter serves as a summary of the key elements of the full protocol. More... »

PAGES

548

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-020-04488-8

DOI

http://dx.doi.org/10.1186/s13063-020-04488-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1128626706

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32560746


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aerosols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Betacoronavirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "COVID-19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Coronavirus Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxyribonuclease I", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pandemics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Viral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Respiratory Distress Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "SARS-CoV-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trachea", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Program in Cellular and Molecular Medicine, Boston Children\u2019s Hospital, Harvard Medical School, 02115, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.38142.3c", 
          "name": [
            "Biological Resource Center, Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France", 
            "Laboratory of Vascular Translational Science, U1148 INSERM, Universit\u00e9 de Paris, Paris, France", 
            "Program in Cellular and Molecular Medicine, Boston Children\u2019s Hospital, Harvard Medical School, 02115, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Desilles", 
        "givenName": "J. P.", 
        "id": "sg:person.0621253236.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621253236.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Intensive Care Department, Rothschild Foundation Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.419339.5", 
          "name": [
            "Intensive Care Department, Rothschild Foundation Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gregoire", 
        "givenName": "C.", 
        "id": "sg:person.01270514316.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270514316.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Unit, Rothschild Foundation Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.419339.5", 
          "name": [
            "Clinical Research Unit, Rothschild Foundation Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Cossec", 
        "givenName": "C.", 
        "id": "sg:person.011214631053.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011214631053.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Unit, Rothschild Foundation Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.419339.5", 
          "name": [
            "Clinical Research Unit, Rothschild Foundation Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambert", 
        "givenName": "J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Unit, Rothschild Foundation Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.419339.5", 
          "name": [
            "Clinical Research Unit, Rothschild Foundation Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mophawe", 
        "givenName": "O.", 
        "id": "sg:person.010260035007.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010260035007.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CHRU Nancy, P\u00f4le d\u2019Anesth\u00e9sie-R\u00e9animation, 29 Avenue de Lattre de Tassigny, 54000, Nancy, France", 
          "id": "http://www.grid.ac/institutes/grid.410527.5", 
          "name": [
            "CHRU Nancy, P\u00f4le d\u2019Anesth\u00e9sie-R\u00e9animation, 29 Avenue de Lattre de Tassigny, 54000, Nancy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Losser", 
        "givenName": "M. R.", 
        "id": "sg:person.01050254634.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050254634.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de R\u00e9animation Polyvalente, Centre Hospitalier de Valenciennes, Avenue D\u00e9sandrouin, 59322, Valenciennes, France", 
          "id": "http://www.grid.ac/institutes/grid.418063.8", 
          "name": [
            "Service de R\u00e9animation Polyvalente, Centre Hospitalier de Valenciennes, Avenue D\u00e9sandrouin, 59322, Valenciennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambiotte", 
        "givenName": "F.", 
        "id": "sg:person.012322427055.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012322427055.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CHR Metz-Thionville-Site de Mercy, Service de R\u00e9animation Polyvalente, 1 All\u00e9e du Ch\u00e2teau, 57350, Ars-Laquenexy, France", 
          "id": "http://www.grid.ac/institutes/grid.489915.8", 
          "name": [
            "CHR Metz-Thionville-Site de Mercy, Service de R\u00e9animation Polyvalente, 1 All\u00e9e du Ch\u00e2teau, 57350, Ars-Laquenexy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Tacon", 
        "givenName": "S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Intensive Care Department, Rothschild Foundation Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.419339.5", 
          "name": [
            "Intensive Care Department, Rothschild Foundation Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cantier", 
        "givenName": "M.", 
        "id": "sg:person.0620120441.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620120441.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Intensive Care Department, Rothschild Foundation Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.419339.5", 
          "name": [
            "Intensive Care Department, Rothschild Foundation Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Engrand", 
        "givenName": "N.", 
        "id": "sg:person.01324642571.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324642571.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Intensive Care Department, Rothschild Foundation Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.419339.5", 
          "name": [
            "Intensive Care Department, Rothschild Foundation Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trouiller", 
        "givenName": "P.", 
        "id": "sg:person.016153276513.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016153276513.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Strasbourg, Facult\u00e9 de M\u00e9decine, F\u00e9d\u00e9ration de M\u00e9decine Translationnelle de Strasbourg (FMTS), EA3072, Strasbourg, France", 
          "id": "http://www.grid.ac/institutes/grid.11843.3f", 
          "name": [
            "H\u00f4pitaux Universitaires de Strasbourg, H\u00f4pital de Hautepierre, Service d\u2019Anesth\u00e9sie-R\u00e9animation Chirurgicale, 1 Avenue Moli\u00e8re, 67098, Strasbourg, France", 
            "Universit\u00e9 de Strasbourg, Facult\u00e9 de M\u00e9decine, F\u00e9d\u00e9ration de M\u00e9decine Translationnelle de Strasbourg (FMTS), EA3072, Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pottecher", 
        "givenName": "J.", 
        "id": "sg:person.0703513103.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703513103.80"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2020-06-19", 
    "datePublishedReg": "2020-06-19", 
    "description": "ObjectivesSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for the treatment of cystic fibrosis, which cleaves extracellular DNA and may break up cell-free DNA, loosening sticky mucus in the distal airways and reducing NETs-induced toxicity on alveolar pneumocytes. The COVIDornase trial intends to define the impact of aerosolized intra-tracheal dornase alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs.Trial designCOVIDornase is a prospective, randomized, controlled, 2-arm (1:1 ratio), multicentric, open-label clinical trial.ParticipantsThe study will recruit mechanically ventilated patients hospitalized in the intensive care unit (ICU) in the recruiting centres (at the time of writing: The Rothschild foundation hospital in Paris, the Strasbourg university hospitals, and Metz-Thionville hospital) who have been diagnosed with COVID-19 and meet ARDS criteria.Inclusion criteria- Adult patient (age \u2265 18 years old);- Hospitalized in ICU;- With severe COVID-19 pneumonia and ARDS according to Berlin criteria (PaO2/FiO2 < 300 and PEEP > 5 cmH2O);- Intubated for less than 8 days;- With an anticipated duration of mechanical ventilation > 48 hours;- Carrier of an arterial catheter;- For whom 4 PaO2/FiO2 values over the preceding 24 hours are available;Non-inclusion criteria- Known hypersensitivity to dornase alfa or any of its excipients;- Pregnant or breastfeeding status;- Patient under legal protection.Intervention and comparatorIntervention 1, Study groupDornase alfa (Pulmozyme\u00ae, Roche, Switzerland) will be administered by aerosol, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer (Aerogen Solo\u00ae, Aerogen, Ireland). The remainder of the management will be performed in accordance with good clinical practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH2O, tracheal balloon pressure check every 4 hours or automatic device, 30\u00b0 head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30 cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2 < 150, early enteral nutrition, glycemic control and a sedation protocol based on the RASS score.Intervention 2, ComparatorPatients will receive usual care in accordance with good practice (as detailed above), without aerosols.Main outcomesThe primary outcome is the occurrence of at least one grade improvement between D0 (inclusion) and D7 in the ARDS scale severity (Berlin criteria). For instance from \u201csevere\u201d to \u201cmoderate\u201d or from \u201cmoderate\u201d to \u201cmild\u201d.RandomisationAll consecutive patients meeting the inclusion criteria will be randomised 1:1 using an eCRF-based, computer-generated randomisation table, either to the dornase alfa arm or to the control arm. An interim analysis will be performed after inclusion of 20 patients. Inclusions may be stopped at the interim analysis per data safety and monitoring board (DSMB) advice, if statistical analyses conclude on the futility or efficacy of the intervention or by other DSMB decision.Blinding (masking)The participants and caregivers will not be blinded to study group assignment. Those assessing the outcomes will be blinded to study group assignment.Numbers to be randomised (sample size)Fifty patients will be randomized to each group, 100 patients in total.Trial StatusProtocol version number 2, April 29th, 2020. Recruitment is ongoing. The trial started recruitment on the 21st April 2020. We estimate recruitment will finish August 21st 2020.Trial registrationThe trial was registered in ClinicalTrials.gov on 21 April 2020, updated on 8 May 2020. Trial registration number is NCT04355364.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated. This Letter serves as a summary of the key elements of the full protocol.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13063-020-04488-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "acute respiratory distress syndrome", 
      "neutrophil extracellular traps", 
      "damage-associated molecular patterns", 
      "intensive care unit", 
      "respiratory distress syndrome", 
      "cell-free DNA", 
      "distress syndrome", 
      "mechanical ventilation", 
      "interim analysis", 
      "SARS-CoV-2-induced acute respiratory distress syndrome", 
      "open-label clinical trial", 
      "severe COVID-19 pneumonia", 
      "computer-generated randomisation table", 
      "acute respiratory syndrome coronavirus 2", 
      "PaO2/FiO2 values", 
      "respiratory syndrome coronavirus 2", 
      "early enteral nutrition", 
      "PaO2/FiO2", 
      "clearance of secretions", 
      "COVID-19 pneumonia", 
      "TRIAL REGISTRATION NUMBER", 
      "recruitment of neutrophils", 
      "group assignment", 
      "COVID-19 patients", 
      "syndrome coronavirus 2", 
      "good clinical practice", 
      "severe alveolar injury", 
      "full protocol", 
      "ARDS criteria", 
      "alveolar injury", 
      "enteral nutrition", 
      "RASS scores", 
      "usual care", 
      "Berlin criteria", 
      "breastfeeding status", 
      "glycemic control", 
      "primary outcome", 
      "consecutive patients", 
      "severe pneumonia", 
      "dornase alfa", 
      "distal airways", 
      "care unit", 
      "arterial catheter", 
      "sedation protocol", 
      "ParticipantsThe study", 
      "randomisation table", 
      "Trials website", 
      "coronavirus 2", 
      "neuromuscular blockers", 
      "prone position", 
      "control arm", 
      "study protocol", 
      "clinical trials", 
      "extracellular traps", 
      "inclusion criteria", 
      "patients", 
      "recruiting centres", 
      "Scale-Severity", 
      "clinical practice", 
      "registration number", 
      "intervention 2", 
      "alveolar pneumocytes", 
      "cystic fibrosis", 
      "mesh nebulizer", 
      "sticky mucus", 
      "coronavirus disease", 
      "FIO2 values", 
      "anticipated duration", 
      "consecutive days", 
      "lung mucus", 
      "molecular patterns", 
      "alfa", 
      "trials", 
      "grade improvement", 
      "pneumonia", 
      "COVID-19", 
      "lung", 
      "syndrome", 
      "neutrophils", 
      "administration", 
      "severity", 
      "ventilation", 
      "efficacy", 
      "intervention", 
      "outcomes", 
      "mucus", 
      "further damage", 
      "hours", 
      "structured summary", 
      "DNase 1", 
      "recruitment", 
      "days", 
      "safety", 
      "hyperinflammation", 
      "FiO2", 
      "inflammation", 
      "airway", 
      "statistical analysis", 
      "fibrosis", 
      "catheter", 
      "blockers", 
      "arm", 
      "injury", 
      "myeloperoxidase", 
      "data safety", 
      "disease", 
      "pneumocytes", 
      "hypersensitivity", 
      "criteria", 
      "dose", 
      "protocol", 
      "alveoli", 
      "progression", 
      "secretion", 
      "clearance", 
      "care", 
      "caregivers", 
      "drugs", 
      "extracellular DNA", 
      "FDA", 
      "elastase", 
      "treatment", 
      "scores", 
      "total", 
      "eCRF", 
      "nutrition", 
      "summary", 
      "toxicity", 
      "duration", 
      "D7", 
      "status", 
      "participants", 
      "DNA", 
      "futility", 
      "nebulizer", 
      "group", 
      "best practices", 
      "release", 
      "damage", 
      "practice", 
      "toxic compounds", 
      "advice", 
      "dissemination", 
      "management", 
      "remainder", 
      "inclusion", 
      "control", 
      "center", 
      "analysis", 
      "study", 
      "number", 
      "occurrence", 
      "improvement", 
      "protection", 
      "accordance", 
      "patterns", 
      "histones", 
      "samples", 
      "key elements", 
      "carriers", 
      "excipients", 
      "units", 
      "impact", 
      "aerosols", 
      "number 2", 
      "compounds", 
      "files", 
      "D0", 
      "values", 
      "decisions", 
      "websites", 
      "additional files", 
      "interest", 
      "instances", 
      "materials", 
      "position", 
      "table", 
      "formatting", 
      "assignment", 
      "letter", 
      "elements", 
      "backbone", 
      "traps", 
      "legal protection", 
      "board advice"
    ], 
    "name": "Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial", 
    "pagination": "548", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1128626706"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-020-04488-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32560746"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-020-04488-8", 
      "https://app.dimensions.ai/details/publication/pub.1128626706"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_867.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13063-020-04488-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04488-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04488-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04488-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04488-8'


 

This table displays all metadata directly associated to this object as RDF triples.

401 TRIPLES      20 PREDICATES      225 URIs      217 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-020-04488-8 schema:about N3ce7b09c7d404d17b4f078fa263a57a3
2 N4d210ded64db4801a7390e44f8eff499
3 N5da64b2a9861467c82894aa1cbb9025a
4 N6eddac52a7994ba59a34f8074861df16
5 N9f82ad07303b4201ba05d4aed1e47740
6 Na5f7923deb954b21bd94e9a169abc1a8
7 Naac2eb3daaa44d828f2474a5d3df1580
8 Nb44b6294350e4bed8f3f7d78274b4919
9 Nba8c64fe1ade433a8717be2c48a90d7f
10 Nc7b1f9f9b76547a6b0ab2fbaec699be7
11 Nd05c23410e3641bea354846d3ec6a53c
12 Ndb95f3a4528e47fe9c2f4e793d29e21b
13 Ne58babd5c0ca4417b530b9baf346d6ed
14 Nf36963b0546d4b7f9c4bd1a475b7bf47
15 Nf3728a0c4f964a438f77152e012ae531
16 anzsrc-for:11
17 anzsrc-for:1102
18 schema:author Nb1b2ac5bd93a4bb6ba1d1ba2baf5adbd
19 schema:datePublished 2020-06-19
20 schema:datePublishedReg 2020-06-19
21 schema:description ObjectivesSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for the treatment of cystic fibrosis, which cleaves extracellular DNA and may break up cell-free DNA, loosening sticky mucus in the distal airways and reducing NETs-induced toxicity on alveolar pneumocytes. The COVIDornase trial intends to define the impact of aerosolized intra-tracheal dornase alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs.Trial designCOVIDornase is a prospective, randomized, controlled, 2-arm (1:1 ratio), multicentric, open-label clinical trial.ParticipantsThe study will recruit mechanically ventilated patients hospitalized in the intensive care unit (ICU) in the recruiting centres (at the time of writing: The Rothschild foundation hospital in Paris, the Strasbourg university hospitals, and Metz-Thionville hospital) who have been diagnosed with COVID-19 and meet ARDS criteria.Inclusion criteria- Adult patient (age ≥ 18 years old);- Hospitalized in ICU;- With severe COVID-19 pneumonia and ARDS according to Berlin criteria (PaO2/FiO2 < 300 and PEEP > 5 cmH2O);- Intubated for less than 8 days;- With an anticipated duration of mechanical ventilation > 48 hours;- Carrier of an arterial catheter;- For whom 4 PaO2/FiO2 values over the preceding 24 hours are available;Non-inclusion criteria- Known hypersensitivity to dornase alfa or any of its excipients;- Pregnant or breastfeeding status;- Patient under legal protection.Intervention and comparatorIntervention 1, Study groupDornase alfa (Pulmozyme®, Roche, Switzerland) will be administered by aerosol, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer (Aerogen Solo®, Aerogen, Ireland). The remainder of the management will be performed in accordance with good clinical practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH2O, tracheal balloon pressure check every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30 cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2 < 150, early enteral nutrition, glycemic control and a sedation protocol based on the RASS score.Intervention 2, ComparatorPatients will receive usual care in accordance with good practice (as detailed above), without aerosols.Main outcomesThe primary outcome is the occurrence of at least one grade improvement between D0 (inclusion) and D7 in the ARDS scale severity (Berlin criteria). For instance from “severe” to “moderate” or from “moderate” to “mild”.RandomisationAll consecutive patients meeting the inclusion criteria will be randomised 1:1 using an eCRF-based, computer-generated randomisation table, either to the dornase alfa arm or to the control arm. An interim analysis will be performed after inclusion of 20 patients. Inclusions may be stopped at the interim analysis per data safety and monitoring board (DSMB) advice, if statistical analyses conclude on the futility or efficacy of the intervention or by other DSMB decision.Blinding (masking)The participants and caregivers will not be blinded to study group assignment. Those assessing the outcomes will be blinded to study group assignment.Numbers to be randomised (sample size)Fifty patients will be randomized to each group, 100 patients in total.Trial StatusProtocol version number 2, April 29th, 2020. Recruitment is ongoing. The trial started recruitment on the 21st April 2020. We estimate recruitment will finish August 21st 2020.Trial registrationThe trial was registered in ClinicalTrials.gov on 21 April 2020, updated on 8 May 2020. Trial registration number is NCT04355364.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated. This Letter serves as a summary of the key elements of the full protocol.
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf N1a27c5cbf6314c17ae97ec3e37d0eb42
25 Nad396e038c5f442eb6fb0685ff871d26
26 sg:journal.1297400
27 schema:keywords ARDS criteria
28 Berlin criteria
29 COVID-19
30 COVID-19 patients
31 COVID-19 pneumonia
32 D0
33 D7
34 DNA
35 DNase 1
36 FDA
37 FIO2 values
38 FiO2
39 PaO2/FiO2
40 PaO2/FiO2 values
41 ParticipantsThe study
42 RASS scores
43 SARS-CoV-2-induced acute respiratory distress syndrome
44 Scale-Severity
45 TRIAL REGISTRATION NUMBER
46 Trials website
47 accordance
48 acute respiratory distress syndrome
49 acute respiratory syndrome coronavirus 2
50 additional files
51 administration
52 advice
53 aerosols
54 airway
55 alfa
56 alveolar injury
57 alveolar pneumocytes
58 alveoli
59 analysis
60 anticipated duration
61 arm
62 arterial catheter
63 assignment
64 backbone
65 best practices
66 blockers
67 board advice
68 breastfeeding status
69 care
70 care unit
71 caregivers
72 carriers
73 catheter
74 cell-free DNA
75 center
76 clearance
77 clearance of secretions
78 clinical practice
79 clinical trials
80 compounds
81 computer-generated randomisation table
82 consecutive days
83 consecutive patients
84 control
85 control arm
86 coronavirus 2
87 coronavirus disease
88 criteria
89 cystic fibrosis
90 damage
91 damage-associated molecular patterns
92 data safety
93 days
94 decisions
95 disease
96 dissemination
97 distal airways
98 distress syndrome
99 dornase alfa
100 dose
101 drugs
102 duration
103 eCRF
104 early enteral nutrition
105 efficacy
106 elastase
107 elements
108 enteral nutrition
109 excipients
110 extracellular DNA
111 extracellular traps
112 fibrosis
113 files
114 formatting
115 full protocol
116 further damage
117 futility
118 glycemic control
119 good clinical practice
120 grade improvement
121 group
122 group assignment
123 histones
124 hours
125 hyperinflammation
126 hypersensitivity
127 impact
128 improvement
129 inclusion
130 inclusion criteria
131 inflammation
132 injury
133 instances
134 intensive care unit
135 interest
136 interim analysis
137 intervention
138 intervention 2
139 key elements
140 legal protection
141 letter
142 lung
143 lung mucus
144 management
145 materials
146 mechanical ventilation
147 mesh nebulizer
148 molecular patterns
149 mucus
150 myeloperoxidase
151 nebulizer
152 neuromuscular blockers
153 neutrophil extracellular traps
154 neutrophils
155 number
156 number 2
157 nutrition
158 occurrence
159 open-label clinical trial
160 outcomes
161 participants
162 patients
163 patterns
164 pneumocytes
165 pneumonia
166 position
167 practice
168 primary outcome
169 progression
170 prone position
171 protection
172 protocol
173 randomisation table
174 recruiting centres
175 recruitment
176 recruitment of neutrophils
177 registration number
178 release
179 remainder
180 respiratory distress syndrome
181 respiratory syndrome coronavirus 2
182 safety
183 samples
184 scores
185 secretion
186 sedation protocol
187 severe COVID-19 pneumonia
188 severe alveolar injury
189 severe pneumonia
190 severity
191 statistical analysis
192 status
193 sticky mucus
194 structured summary
195 study
196 study protocol
197 summary
198 syndrome
199 syndrome coronavirus 2
200 table
201 total
202 toxic compounds
203 toxicity
204 traps
205 treatment
206 trials
207 units
208 usual care
209 values
210 ventilation
211 websites
212 schema:name Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
213 schema:pagination 548
214 schema:productId N23e3ee1dc68c4a2585096a2f191f52a7
215 N6f8fb43d3d4141e897e0bfefa02101bc
216 N9c260dffdfea4b6e956871c280d85df5
217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128626706
218 https://doi.org/10.1186/s13063-020-04488-8
219 schema:sdDatePublished 2022-09-02T16:04
220 schema:sdLicense https://scigraph.springernature.com/explorer/license/
221 schema:sdPublisher N3f275dfacc954645b0322fc45c9461d4
222 schema:url https://doi.org/10.1186/s13063-020-04488-8
223 sgo:license sg:explorer/license/
224 sgo:sdDataset articles
225 rdf:type schema:ScholarlyArticle
226 N0ad2cf578ef34f309430ab7093d18d6a rdf:first sg:person.0703513103.80
227 rdf:rest rdf:nil
228 N0e0e3c20ac2c4b1b898b07809dbb88ca rdf:first Nfb2d305b798240fdb4dec723857802e3
229 rdf:rest Nd5449427547c48f0acf42cf0c250f06c
230 N1a27c5cbf6314c17ae97ec3e37d0eb42 schema:issueNumber 1
231 rdf:type schema:PublicationIssue
232 N23e3ee1dc68c4a2585096a2f191f52a7 schema:name doi
233 schema:value 10.1186/s13063-020-04488-8
234 rdf:type schema:PropertyValue
235 N2c4dc9583072408589a444a51faebb78 rdf:first N9aa76cc20fe143039af822ec10acb8f7
236 rdf:rest N82096f54c3274c1b9d307e8ccc533293
237 N3ce7b09c7d404d17b4f078fa263a57a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
238 schema:name Pneumonia, Viral
239 rdf:type schema:DefinedTerm
240 N3f275dfacc954645b0322fc45c9461d4 schema:name Springer Nature - SN SciGraph project
241 rdf:type schema:Organization
242 N4d210ded64db4801a7390e44f8eff499 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
243 schema:name Adult
244 rdf:type schema:DefinedTerm
245 N5da64b2a9861467c82894aa1cbb9025a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
246 schema:name Humans
247 rdf:type schema:DefinedTerm
248 N6eddac52a7994ba59a34f8074861df16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
249 schema:name Pandemics
250 rdf:type schema:DefinedTerm
251 N6f8fb43d3d4141e897e0bfefa02101bc schema:name pubmed_id
252 schema:value 32560746
253 rdf:type schema:PropertyValue
254 N82096f54c3274c1b9d307e8ccc533293 rdf:first sg:person.010260035007.62
255 rdf:rest Nd5fba777d4a341fab2e8a6a52d7edbfd
256 N9aa76cc20fe143039af822ec10acb8f7 schema:affiliation grid-institutes:grid.419339.5
257 schema:familyName Lambert
258 schema:givenName J.
259 rdf:type schema:Person
260 N9c260dffdfea4b6e956871c280d85df5 schema:name dimensions_id
261 schema:value pub.1128626706
262 rdf:type schema:PropertyValue
263 N9f82ad07303b4201ba05d4aed1e47740 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
264 schema:name Randomized Controlled Trials as Topic
265 rdf:type schema:DefinedTerm
266 Na5f7923deb954b21bd94e9a169abc1a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
267 schema:name COVID-19
268 rdf:type schema:DefinedTerm
269 Na6dabf6490cd4f35b7f36ed5799ba036 rdf:first sg:person.012322427055.26
270 rdf:rest N0e0e3c20ac2c4b1b898b07809dbb88ca
271 Naac2eb3daaa44d828f2474a5d3df1580 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
272 schema:name Deoxyribonuclease I
273 rdf:type schema:DefinedTerm
274 Nad396e038c5f442eb6fb0685ff871d26 schema:volumeNumber 21
275 rdf:type schema:PublicationVolume
276 Nb116cfac390342f4b292a9949e597528 rdf:first sg:person.01270514316.15
277 rdf:rest Nd4cfb5cde6b74f81b51b14763d4a2efc
278 Nb1b2ac5bd93a4bb6ba1d1ba2baf5adbd rdf:first sg:person.0621253236.82
279 rdf:rest Nb116cfac390342f4b292a9949e597528
280 Nb44b6294350e4bed8f3f7d78274b4919 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
281 schema:name Recombinant Proteins
282 rdf:type schema:DefinedTerm
283 Nb4835121ee464706b5deb28474b1f408 rdf:first sg:person.016153276513.45
284 rdf:rest N0ad2cf578ef34f309430ab7093d18d6a
285 Nba8c64fe1ade433a8717be2c48a90d7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
286 schema:name Betacoronavirus
287 rdf:type schema:DefinedTerm
288 Nc7b1f9f9b76547a6b0ab2fbaec699be7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
289 schema:name Prospective Studies
290 rdf:type schema:DefinedTerm
291 Nc988551acf884a2eb1222a415e56d96f rdf:first sg:person.01324642571.72
292 rdf:rest Nb4835121ee464706b5deb28474b1f408
293 Nd05c23410e3641bea354846d3ec6a53c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
294 schema:name Aerosols
295 rdf:type schema:DefinedTerm
296 Nd4cfb5cde6b74f81b51b14763d4a2efc rdf:first sg:person.011214631053.58
297 rdf:rest N2c4dc9583072408589a444a51faebb78
298 Nd5449427547c48f0acf42cf0c250f06c rdf:first sg:person.0620120441.58
299 rdf:rest Nc988551acf884a2eb1222a415e56d96f
300 Nd5fba777d4a341fab2e8a6a52d7edbfd rdf:first sg:person.01050254634.49
301 rdf:rest Na6dabf6490cd4f35b7f36ed5799ba036
302 Ndb95f3a4528e47fe9c2f4e793d29e21b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
303 schema:name SARS-CoV-2
304 rdf:type schema:DefinedTerm
305 Ne58babd5c0ca4417b530b9baf346d6ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
306 schema:name Respiratory Distress Syndrome
307 rdf:type schema:DefinedTerm
308 Nf36963b0546d4b7f9c4bd1a475b7bf47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
309 schema:name Coronavirus Infections
310 rdf:type schema:DefinedTerm
311 Nf3728a0c4f964a438f77152e012ae531 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
312 schema:name Trachea
313 rdf:type schema:DefinedTerm
314 Nfb2d305b798240fdb4dec723857802e3 schema:affiliation grid-institutes:grid.489915.8
315 schema:familyName Le Tacon
316 schema:givenName S.
317 rdf:type schema:Person
318 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
319 schema:name Medical and Health Sciences
320 rdf:type schema:DefinedTerm
321 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
322 schema:name Cardiorespiratory Medicine and Haematology
323 rdf:type schema:DefinedTerm
324 sg:journal.1297400 schema:issn 1468-6708
325 1745-6215
326 schema:name Trials
327 schema:publisher Springer Nature
328 rdf:type schema:Periodical
329 sg:person.010260035007.62 schema:affiliation grid-institutes:grid.419339.5
330 schema:familyName Mophawe
331 schema:givenName O.
332 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010260035007.62
333 rdf:type schema:Person
334 sg:person.01050254634.49 schema:affiliation grid-institutes:grid.410527.5
335 schema:familyName Losser
336 schema:givenName M. R.
337 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050254634.49
338 rdf:type schema:Person
339 sg:person.011214631053.58 schema:affiliation grid-institutes:grid.419339.5
340 schema:familyName Le Cossec
341 schema:givenName C.
342 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011214631053.58
343 rdf:type schema:Person
344 sg:person.012322427055.26 schema:affiliation grid-institutes:grid.418063.8
345 schema:familyName Lambiotte
346 schema:givenName F.
347 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012322427055.26
348 rdf:type schema:Person
349 sg:person.01270514316.15 schema:affiliation grid-institutes:grid.419339.5
350 schema:familyName Gregoire
351 schema:givenName C.
352 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270514316.15
353 rdf:type schema:Person
354 sg:person.01324642571.72 schema:affiliation grid-institutes:grid.419339.5
355 schema:familyName Engrand
356 schema:givenName N.
357 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324642571.72
358 rdf:type schema:Person
359 sg:person.016153276513.45 schema:affiliation grid-institutes:grid.419339.5
360 schema:familyName Trouiller
361 schema:givenName P.
362 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016153276513.45
363 rdf:type schema:Person
364 sg:person.0620120441.58 schema:affiliation grid-institutes:grid.419339.5
365 schema:familyName Cantier
366 schema:givenName M.
367 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620120441.58
368 rdf:type schema:Person
369 sg:person.0621253236.82 schema:affiliation grid-institutes:grid.38142.3c
370 schema:familyName Desilles
371 schema:givenName J. P.
372 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621253236.82
373 rdf:type schema:Person
374 sg:person.0703513103.80 schema:affiliation grid-institutes:grid.11843.3f
375 schema:familyName Pottecher
376 schema:givenName J.
377 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703513103.80
378 rdf:type schema:Person
379 grid-institutes:grid.11843.3f schema:alternateName Université de Strasbourg, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), EA3072, Strasbourg, France
380 schema:name Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Service d’Anesthésie-Réanimation Chirurgicale, 1 Avenue Molière, 67098, Strasbourg, France
381 Université de Strasbourg, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), EA3072, Strasbourg, France
382 rdf:type schema:Organization
383 grid-institutes:grid.38142.3c schema:alternateName Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Harvard Medical School, 02115, Boston, MA, USA
384 schema:name Biological Resource Center, Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France
385 Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, Paris, France
386 Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Harvard Medical School, 02115, Boston, MA, USA
387 rdf:type schema:Organization
388 grid-institutes:grid.410527.5 schema:alternateName CHRU Nancy, Pôle d’Anesthésie-Réanimation, 29 Avenue de Lattre de Tassigny, 54000, Nancy, France
389 schema:name CHRU Nancy, Pôle d’Anesthésie-Réanimation, 29 Avenue de Lattre de Tassigny, 54000, Nancy, France
390 rdf:type schema:Organization
391 grid-institutes:grid.418063.8 schema:alternateName Service de Réanimation Polyvalente, Centre Hospitalier de Valenciennes, Avenue Désandrouin, 59322, Valenciennes, France
392 schema:name Service de Réanimation Polyvalente, Centre Hospitalier de Valenciennes, Avenue Désandrouin, 59322, Valenciennes, France
393 rdf:type schema:Organization
394 grid-institutes:grid.419339.5 schema:alternateName Clinical Research Unit, Rothschild Foundation Hospital, Paris, France
395 Intensive Care Department, Rothschild Foundation Hospital, Paris, France
396 schema:name Clinical Research Unit, Rothschild Foundation Hospital, Paris, France
397 Intensive Care Department, Rothschild Foundation Hospital, Paris, France
398 rdf:type schema:Organization
399 grid-institutes:grid.489915.8 schema:alternateName CHR Metz-Thionville-Site de Mercy, Service de Réanimation Polyvalente, 1 Allée du Château, 57350, Ars-Laquenexy, France
400 schema:name CHR Metz-Thionville-Site de Mercy, Service de Réanimation Polyvalente, 1 Allée du Château, 57350, Ars-Laquenexy, France
401 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...